For our September #radonc journal club we will discuss twice-daily versus daily chemoradiation for limited stage small cell lung cancer (LS-SCLC). Twice-daily radiation has been controversial for some time – do the results of the CONVERT trial mean the debate is settled?
Our article is:
The article is free for download, thanks to the CONVERT Study Team and The Lancet Oncology. For the protocol and supplementary materials, click here.
The lead author, Prof Corinne Faivre-Finn PhD of the Christie NHS Foundation Trust, will join us for the weekend and will discuss at a live journal hour Sunday September 17th at 11AM- 12PM Central Standard Time, 5-6 PM London. We will focus on the following topics:
T1. Â Chemoradiotherapy is the standard for limited stage small cell lung cancer. What do most people do currently for the radiation and chemotherapy regimens?
T2. Â What were the aim and methods of this study?
T3.  What were the results, and how do they fit into current standards for treatment delivery?
T4. Â Failure rates remain high in both arms. What areas of future research in radiotherapy should we pursue to further improve outcomes in LS-SCLC?
We will start open chat 6 AM CST Saturday September 16th to include global participation.
- Here are guidelines on how to sign up and participate
- Read our disclaimer for ways to keep it rewarding and professional. If you’re not ready, just lurk and tune into the conversation.
- If you feel like getting fancy, feel free to add #lcsm to your tweets and share with the lung cancer community on twitter. Just don’t forget the #radonc tag!
Any suggestions? Leave a comment or tweet us at @Rad_Nation. And please join us this weekend!
